Malignant Hyperthermia Susceptibility Panel
A 3-gene panel for assessing malignant hyperthermia susceptibility, powered by the Helix Exome+® platform for comprehensive anesthesia risk evaluation.
6-9 days
≤ 5 days
Test Description
This panel evaluates 3 genes associated with malignant hyperthermia.
Have Questions?
Our team is available Monday through Friday, 9am-5pm Pacific Time.
Indications for Testing
A relevant personal and/or family history suggestive of Malignant Hyperthermia Susceptibility (MHS) or patients preparing to be exposed to anesthetics for the first time.
Methodology
This test utilizes next-generation sequencing to detect single nucleotide variants, insertions and deletions up to 20 bp, and copy number variants in genes associated with Malignant Hyperthermia Susceptibility (MHS).This panel includes 3 genes that are associated with MHS.
Technical Specifications
> 99%
> 99%
> 99%
> 99%
> 90%
CACNA1S: Sensitivity to exon 91 may be reduced. STAC3: Sensitivity to exon 7 may be reduced.
GRCh38
Genes Tested
Showing 3 of 3 genes in this panel